Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment.
Clin Rheumatol. 2007 Feb;26(2):258-60. Epub 2006 Jul 6. PMID: 16683176
Department of Internal Medicine, Euroclinic Hospital, 9 Athanasiadou str, 115 21, Athens, Greece. email@example.com
Antitumor necrosis alpha agents have been successfully used for the treatment of rheumatoid and seronegative arthritis, Crohn's disease, psoriasis, and severe cases of vasculitis. Several side effects have been observed in patients receiving these agents including hypersensitivity reactions, infections, drug-induced lupus, or demyelinating syndromes. The presence of peripheral neuropathy has been reported only in isolated cases. We describe two cases of peripheral neuropathy which occurred in patients with rheumatoid arthritis receiving infliximab treatment, one with multifocal motor neuropathy with conduction block and another with axonal sensory polyneuropathy, reversed upon discontinuation of infliximab and intravenous gammaglobulin treatment.